Fig. 7.

HP-MTi notably enhanced the STI around implants in both inflammation phase and remodeling phase. (A) Schematic illustration of in vivo evaluation plan. (B) Representative IF images of iNOS and F4/80 and in the soft tissue around implants from different groups, and (C) quantitative analysis. Scale bar, 20 μm. (D) Representative IF images of Arg-1 and F4/80 and in the soft tissue around implants from different groups, and (E) quantitative analysis. Scale bar, 20 μm. (F) Levels of IL-6, TNF-α, IL-10 and TGF-β in the soft tissue around implants from different groups. (G) Relative mRNA level of IL-6, TNF-α, IL-10 and TGF-β in the soft tissue around implants from different groups. (H) Representative VG and Masson staining image of soft tissue around implants from different groups. Scale bar, 200 μm. Magnify scale bar,100 μm. (I) Representative laser confocal microscopy images and (J)quantitative analysis of CD31 in the soft tissue around implants form different groups. Scale bar, 50 μm. (K)Quantitative analysis of collagen density. (L) Level of COL1A and VEGFA in the soft tissue around implants form different groups. (M) Relative mRNA level of COL1A and VEGFA in the soft tissue around implants form different groups. The value is expressed as the means ± SD, with a minimum sample size of 3. (ns, not significant; ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; and ∗∗∗∗P < 0.0001.)